



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/358,835	01/23/2009	Charles John Talkowski	PP0042USNA	3258
23906	7590	05/24/2013	EXAMINER	
E I DU PONT DE NEMOURS AND COMPANY LEGAL PATENT RECORDS CENTER BARLEY MILL PLAZA 25 4417 LANCASTER PIKE WILMINGTON, DE 19805			JONES JR., ROBERT STOCKTON	
			ART UNIT	PAPER NUMBER
			1762	
			NOTIFICATION DATE	DELIVERY MODE
			05/24/2013	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PTO-Legal.PRC@usa.dupont.com



Patent Trial and Appeal Board

Informative

Standard Operating Procedure 2

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Ex parte CHARLES JOHN TALKOWSKI

Appeal 2012-002290
Application 12/358,835
Technology Center 1700

Before FRED E. McKELVEY, GEORGE C. BEST and DONNA M. PRAISS,
Administrative Patent Judges.

McKELVEY, *Administrative Patent Judge.*

DECISION ON APPEAL

Statement of the case

1 E.I. du Pont de Nemours and Company (“applicant”), the real party in
2 interest (Brief, page 1), seeks review under 35 U.S.C. § 134(a) of a final rejection
3 dated 22 December 2010.

4 The application was filed in the USPTO on 23 January 2009.

5 The application on appeal claims priority of Provisional Application
6 61/023,220, filed 24 January 2008.

7 The application has been published as U.S. Patent Application Publication
8 2009/0192268 A1 (30 July 2009).

9 In support of prior art rejections, the Examiner relies on the following
10 evidence.

Chen et al. “Chen”	U.S. Patent 5,554,120	10 Sept. 1996
Kurian et al. “Kurian”	U.S. Patent 6,245,844 B1	12 June 2001
Rolland et al. “Rolland”	U.S. Published Patent Application 2005/0112372 A1	26 May 2005
Wakabayashi et al. “Wakabayashi 1”	<i>Coassembly of Fatty Acid Salts and Semicrystalline Ionomers,</i> AMERICAN PHYSICAL SOCIETY ABSTRACT #N17.004 APS March 2003 meeting	Mar. 2003
C. E. Carraher, Jr. “Carraher”	POLYMER CHEMISTRY, pages 49-53 (ISBN 0-203-91130) (6th ed.)	2003

11 Applicant does not contest the prior art status of the Examiner’s evidence.

1 We mention the following additional evidence in this opinion:

Wakabayashi et al. “Wakabayashi 2”	<i>Ethylene/(meth)acrylic acid ionomers plasticized and reinforced by metal soaps</i> , 47 POLYMER 2874-2883	2006
K. Wakabayashi “Wakabayashi 3”	<i>Structure-Property Relationships in Semicrystalline Copolymers and Ionomers</i> , Ph.D. Thesis Princeton University	Jan. 2006

2 We have jurisdiction under 35 U.S.C. § 134(a).

3 Claims on appeal

4 Claims 1-20 are on appeal. Brief, page 1; Answer, page 3.

5 Claim 1, which we reproduce from the Claims Appendix of the Brief
6 (page 15), reads [matter in brackets and some indentation added; principal
7 limitations in issue in italics]:

8 A thermoplastic composition comprising or produced from,
9 based on the weight of the thermoplastic composition, [A] about 70 to
10 about 99.8 % of a polyester composition and [B] a modifier wherein

11 [1] the polyester composition [A] comprises poly(trimethylene
12 terephthalate) or poly(tetramethylene terephthalate), or combinations
13 thereof;

14 [2] the modifier [B] comprises [2.1] *at least one aliphatic,*
15 *monofunctional organic acid*, [2.2] *at least one ionomer derived from*
16 *an ethylene acid copolymer*, and [2.3] optionally at least one ethylene
17 ester copolymer;

18 [3] the organic acid [2.1] has 4 to 36 carbon atoms, optionally
19 substituted with a C₁₋₈ alkyl group;

1 [4] the [ethylene] acid copolymer [basis of ionomer 2.2]
2 comprises [4.1] copolymerized comonomers of ethylene, [4.2] a^[1]
3 copolymerized comonomers of at least one C₃₋₈ α,β-ethylenically
4 unsaturated carboxylic acid, and [4.3] optionally a copolymerized
5 comonomer of at least one C₃₋₈ α,β-ethylenically unsaturated
6 carboxylic acid ester;

7 [5] the ethylene ester copolymer [2.3] wherein^[2] comprises,
8 based on the weight of the ethylene ester copolymer,

9 (i) about 20 to about 95% of copolymerized units of
10 ethylene,

11 (ii) 0 to about 25% of copolymerized units of at least one
12 ester of the formula CH₂=C(R¹)CO₂R², and

13 (iii) 0 to about 80 weight^[3] % of copolymerized units of
14 at least one ester of the formula CH₂=C(R³)CO₂R⁴;

15 [wherein] (ii) and (iii) cannot both be 0 weight^[4] %;

16 R¹ is hydrogen or an alkyl group having 1 to 6 carbon
17 atoms;

18 R² is a glycidyl group;

19 R³ is hydrogen or an alkyl group having 1 to 8 carbon
20 atoms; and

21 R⁴ is an alkyl group having 1 to 8 carbon atoms;

¹ The word “a” appears to be unnecessary.

² The word “wherein” appears to be unnecessary.

³ The word “weight” appears to be unnecessary in view of the language “based on the weight of the ethylene ester copolymer” set out earlier in the claim.

⁴ See n.3.

1 [6] from about 75 % to about 100 % of the combined
2 acid moieties in the modifier [B] are neutralized to form salts
3 with metal cations; and

4 [7] the cations [6] comprise at least about 75
5 equivalent % of *magnesium, calcium, zinc, or combinations of*
6 *two or more thereof.*

7 The rejections

8 In the Answer, the Examiner maintains the following rejections.

9 Rejection 1: Claims 1-4, 14-16 and 18-19 stand rejected under § 103 as
10 being unpatentable over Chen and Wakabayashi 1. Answer, page 5.

11 In presenting its appeal, applicant does not separately argue the patentability
12 of Claims 2-4, 14-16 and 18-19 apart from Claim 1. Accordingly, we address only
13 Claim 1. 37 C.F.R. § 41.37(c)(1)(vii).

14 Rejection 2: Claims 5-7 stand rejected under § 103 as being unpatentable
15 over Chen, Wakabayashi 1 and Rolland. Answer, page 11.

16 In presenting its appeal of Rejection 2, applicant does not make an argument
17 apart from the arguments presented with respect to Rejection 1. The patentability
18 of Claims 5-7 therefore stands or falls with the patentability of Claim 1.

19 Rejection 3: Claims 8-9, 12-13, 17 and 20 stand rejected under § 103 as
20 being unpatentable over Chen, Wakabayashi 1 and Kurian. Answer, page 13.

21 In presenting its appeal of Rejection 3, applicant does not make an argument
22 apart from the arguments presented with respect to Rejection 1. The patentability
23 of Claims 8-9, 12-13, 17 and 20 therefore stands or falls with the patentability of
24 Claim 1.

25 Rejection 4: Claims 10-11 stand rejected under § 103 as unpatentable over
26 Chen, Wakabayashi 1, Kurian and Rolland. Answer, page 16.

1 reproduced *supra*], improving such mechanical strength inevitably
2 increases the melt viscosity of PTT thereby making the PTT more
3 difficult to be melt-processed because it is less fluid at melt
4 temperatures and may decompose. Producing a higher molecular
5 weight PTT also improves the mechanical strength, but also increases
6 the PTT melt viscosity. Use of impact modifier (reinforcement) may
7 also increase the mechanical strength, but inevitably increase[s] the
8 melt viscosity, again, making the PTT more difficult to be melt-
9 processed.

10 Brief, page 5 (with some minor grammatical modifications to the quoted material).

11 Applicant says that the problem it sought to address “was . . . how to
12 eliminate the increase in melt viscosity of PTT, as a result of the modification by
13 addition of impact modifier to the PTT.” Brief page 5. Applicant goes on to say
14 that it would have been “[e]ven more desirable . . . to reduce the absolute melt
15 viscosity of the PTT without substantial reduction in molecular weight and
16 consequently avoid the loss of mechanical strength of the PTT.” *Id.*

17 Chen

18 Chen’s invention relates generally to polymer blends that can be extruded,
19 molded, or otherwise formed into articles of manufacture having certain desired
20 characteristics. Chen, col. 1:9-12. For example, the Chen polymer blends can be
21 processed to form medical catheters. More particularly, Chen concerns a balloon
22 material for medical balloon dilatation catheters made from blends of (1) a first
23 crystalline polymer component, and (2) a second softening polymer component.
24 The balloon material can also include (3) a third compatibilizing polymer
25 component. While the Chen invention relates generally to polymer blends, Chen

1 discusses the invention in terms of preferred end uses in medical devices such as
2 catheters and dilatation balloons. Chen, col. 1:9-22.

3 According to Chen, it was desirable to provide a polymeric blend for
4 balloons for balloon dilatation catheters with a combination of the best features of
5 the softer balloon materials and the stronger balloon materials, including good
6 flexibility with (1) a thin, low profile, (2) high resistance to fatigue, (3) low
7 compliance, and (4) high burst strength, with (5) a lower susceptibility to defects
8 through mechanical handling, and (6) a lower susceptibility to pin-hole defects,
9 compared with balloons made from PET. Chen, col. 2:30-38.

10 Difference between Claim 1 and Chen

11 Claim 1 requires a modifier [B] that includes at least a combination of both
12 an organic acid (Item [2.1]) and an ionomer (Item [2.2]).

13 The essential difference between the subject matter of Claim 1 and the
14 subject matter described by Chen is that Chen does not describe the use of a second
15 softening polymer component that is a *combination* of (1) an organic acid with
16 (2) an ionomer (Claim 1, Item [2.2]). Instead, Chen describes the use of the
17 ionomer, *i.e.*, Chen's "second polymeric component". Chen, col. 2:54-55;
18 col. 3:37-57; col. 5:40 to col. 6:44. *See also* Answer, page 19 (discussing the
19 difference).

20 Wakabayashi 1, Wakabayashi 2 and Wakabayashi 3

21 To overcome the difference, the Examiner turned to Wakabayashi 1.

22 Wakabayashi 1 is an Abstract of a presentation that was to be made at a
23 March 3-7, 2003 meeting of the American Physical Society. We do not know if
24 the presentation occurred. An attempt by personnel at the Board to locate an
25 underlying paper upon which the Abstract might have been based also was not

1 successful. As a result of that attempt, however, Wakabayashi 2 and
2 Wakabayashi 3 came to our attention.

3 Based on all three Wakabayashi publications, we understand that Katsuyuki
4 Wakabayashi (now Dr. Wakabayashi) was a graduate student at Princeton
5 University in 2003 working under the direction of Dr. Richard A. Register.
6 Dr. Register is a professor and polymer researcher at Princeton University. Based
7 on the Wakabayashi publications, it appears that research which may have begun
8 as early as 2003 (Wakabayashi 1) was probably completed in 2005-2006.
9 Wakabayashi 2 and Wakabayashi 3 were published in 2006.

10 Applicant DuPont likely knew of the Wakabayashi/Register research.
11 Wakabayashi 2, page 2875, col. 2 (“[t]he preparation of ionomer:metal soap
12 blends was carried out at DuPont by melt mixing”); *id.* at 2883, col. 1; *see also*
13 Wakabayashi 3, page 152. “Dupont Packaging and Industrial Polymers generously
14 provided both financial support for this work and the materials studied herein.
15 The authors are especially grateful to . . . [numerous individuals one of whom
16 was] Dr. George Prejean of DuPont for providing all the materials employed
17 herein, often on demand.” Wakabayashi 2, page 2883, col. 1. *See also*
18 Wakabayashi 3, page xv. DuPont provided copolymers for Wakabayashi’s
19 research. Wakabayashi 3, page 88; *see also* Wakabayashi 3, page 150. Melt index
20 measurements were conducted at DuPont. Wakabayashi 3, page 160.

21 The Wakabayashi publications describe *blends* of magnesium aliphatic acid
22 salts (magnesium stearate and magnesium oleate) with magnesium neutralized
23 ethylene-alkyl acrylate-(meth)acrylic acid terpolymer ionomers. Wakabayashi 1
24 states that a magnesium neutralized ionomer and magnesium stearate coexist and
25 that no phase separation was observed.

1 Wakabayashi 2 indicates that typical E/(M)AA ionomers are semi-
2 crystalline, with crystallinity depending on the content of acid comonomer.
3 Page 2878, col. 1, first full paragraph, and page 2875, Table 1; *see also*
4 Wakabayashi 3, pages 161-62.

5 The acid (also referred to as “soaps” or “metal soaps”) in the Wakabayashi
6 blends prevents formation of a percolated hard phase. Wakabayashi 3, page 166.
7 A hard phase is something Chen seeks to avoid with respect to its softening second
8 polymer component.

9 Applicant is using a known acid/ionomer blend (Wakabayashi 1,
10 Wakabayashi 2 and Wakabayashi 3) consistent with a known purpose (Chen’s
11 second polymeric component) to achieve an expected result—a composition useful
12 for Chen’s purpose. Use of known materials for a known purpose is evidence of
13 obviousness. *KSR Int’l Co. v. Teleflex Inc.*, 550 U.S. 398, 416 (2007)
14 (combination of familiar elements according to known methods is likely to be
15 obvious when it yields no more than predictable results).

16 Wakabayashi 2 provides a cogent analysis in support of its conclusion that
17 use of magnesium vis-à-vis sodium to accomplish neutralization is desirable. Use
18 of magnesium minimizes or eliminates phase separation and achieves other
19 desirable properties relevant to Chen’s softening second polymer component.

20 **Applicant’s arguments**


21 Chen’s crystalline requirements

22 Applicant maintains that there would be no reason to use the Wakabayashi
23 blends in the Chen combination because use of the blend would have been
24 expected to destroy crystalline structures. Brief, page 12. However, some
25 acid/ionomer blends have more crystalline ionomer than others. Wakabayashi 3,
26 pages 181-82. Obviously, one skilled in the art seeking to minimize crystalline

1 content in Chen's softening second polymer component would have been inclined
2 to use the Wakabayashi blends which do not increase crystalline content.

3 We also find that applicant appears to have overlooked the fact that any
4 emphasis by Chen on crystalline structures relates to Chen's "first polymeric
5 component". According to Chen, the first polymeric component is preferably a
6 relatively strong crystalline polymer. Chen, col. 4:53. The Chen "second
7 polymeric component" is added as a softening polymer. There is no reason why
8 the Chen second polymeric component should need to maintain any *high degree* of
9 crystallization given the purpose for which it is added to the overall Chen
10 composition. Nor has applicant presented any credible evidence that use of the
11 Chen second polymeric composition or the Wakabayashi blends alters in any
12 negative manner the crystalline structure of Chen's first polymeric component.

13 The Examiner found that crystalline regions of a polymer contribute to
14 strength, while amorphous regions (*i.e.*, non-crystalline regions) contribute to
15 flexibility or softness. Answer, page 22. Fig. 2.26 of Carraher illustrates the
16 general physical nature of materials as a function of the amount of crystallinity and
17 molecular weight.



18 Carraher Fig. 2.26 depicts a graph of crystallinity v. molecular weight

1 his endeavor’, but it does not require us to presume full
2 knowledge by the inventor of prior art outside the field of
3 his endeavor, i.e., of ‘non-analogous’ art. In that respect,
4 it only requires us to presume that the inventor would
5 have that ability to select and utilize knowledge from
6 other arts reasonably pertinent to his particular problem
7 which would be expected of a man of ordinary skill in the
8 art to which the subject matter pertains.

9 *Wood* and similar earlier precedent seems to have approached the “non-
10 analogous” art issue from a perspective of an inventor. Notwithstanding *Wood* and
11 similar precedent, and as will become apparent, a “no” answer to both Step 1 and
12 Step 2 does not always compel a decision that a reference is non-analogous and
13 therefore may not be used as a reference in a § 103 context.⁷ Since *Wood*, § 103
14 obviousness considerations have not been restricted to an analysis based solely
15 from an inventor’s point of view. Rather, § 103 analysis focuses on what is
16 claimed apart from the motivation of the inventor. *In re Dillon*, 919 F.2d 688 (Fed.
17 Cir. 1990) (*en banc*), is illustrative.

18 *Dillon* involved the patentability under § 103 of claims directed to a
19 composition comprising (1) fuel and (2) a particular tetra-orthoester. Inventor
20 Dillon discovered that use of the tetra-orthoester in fuel *reduced particulate*
21 *emissions when the fuel was burned*. However, use of the tri- and tetra-orthoesters
22 in fuel to *minimize or eliminate water freezing in fuel transportation pipelines*
23 *valves* in cold weather was taught by a prior art Elliott patent. Preventing water
24 freezing in valves in fuel pipeline transportation systems in cold weather regions of
25 the United States was not a problem which inventor Dillon was trying to solve.
26 Tetra-orthoester prior art did not describe its use in fuel as a means for reducing

⁷ Whether future development of the law results in creation of a Step 3 is a matter we (1) do not foreclose and (2) leave for another day.

1 particulate emissions. However, as *Dillon* notes:

2 Howk teaches use of both tri- and tetra-orthoesters in a
3 similar type of chemical reaction. Elliott teaches their
4 equivalence *for a particular practical use* [*i.e.*,
5 prevention of water freezing].

6 *Id.* at 692.

7 The issue before . . . [the *Dillon*] court . . . [was] whether
8 the Board erred in rejecting as obvious under 35 U.S.C.
9 § 103 claims to Dillon’s new compositions and to the
10 new method of reducing particulate emissions, when the
11 additives in the new compositions are structurally similar
12 to additives in known compositions, having a different
13 use, but the new method of reducing particulate
14 emissions is neither taught nor suggested by the prior art.

15 *Id.* at 691.

16 *Dillon* held that the claimed compositions would have been obvious
17 notwithstanding the different utility discovered by inventor Dillon and that
18 disclosed in the orthoester prior art. *Dillon* notes that:

19 it is not necessary in order to establish a *prima facie* case
20 of obviousness that . . . there be a suggestion in or
21 expectation from *the prior art* that the claimed compound
22 or composition will have the same or a similar utility *as*
23 *one newly discovered by applicant*.

24 *Id.* at 693 (emphasis in original).

25 Subsequent precedent continues *Dillon*’s approach. *See, e.g., In re Kemps,*
26 97 F.3d 1427, 1430 (Fed. Cir. 1996) (“Although the motivation to combine here
27 differs from that of the applicant, the motivation in the prior art to combine the
28 references does not have to be identical to that of the applicant to establish
29 obviousness.”).

30 In *KSR*, the Supreme Court understood the court below to have held in a
31 § 103 context that “unless the ‘prior art references address[ed] the precise problem

1 that the patent was trying to solve,’ the problem would not motivate an inventor to
2 look into those references.” 550 U.S. at 414. However, the Court observed that
3 (italics added):

4 In determining whether the subject matter of a . . . claim
5 is obvious, neither the particular motivation nor the
6 avowed purpose of the patentee controls. What matters
7 is the objective reach of the claim. If the claim extends
8 to what is obvious, it is . . . [unpatentable] under § 103.
9 One of the ways in which a patent’s subject matter can be
10 proved obvious is by noting that there existed at the time
11 of the invention a known problem for which there was an
12 obvious solution *encompassed by the patent’s claims*.

13 *Id.* at 419-20.

14 The Court’s observation is consistent with *Dillon* and *Kemps*. The reason
15 for declining to allow a claim for subject matter that would have been obvious
16 under § 103 is based on the proposition that such allowance withdraws from the
17 public domain subject matter that those skilled in the art should be free to use.
18 *Graham v. John Deere Co.*, 383 U.S. at 6 (patents that remove existent knowledge
19 from the public domain or to restrict free access to materials already available
20 should not be issued); *see also In re Kubin*, 561 F.3d 1351, 1358 (Fed. Cir. 2009)
21 (“[a] patent on such a structure would remove from the public that which is in the
22 public domain by virtue of its inclusion in, or obviousness from, the prior art”); *In*
23 *re Translogic Tech., Inc.*, 504 F.3d 1249, 1259 (Fed. Cir. 2007) (“obvious variants
24 of prior art references are themselves part of the public domain”).

25 It may be true that Chen and applicant set out to solve different problems.
26 However, those practicing the Chen invention should be free to make a
27 modification to that invention by including in the Chen composition the blends
28 described by the Wakabayashi publications. Allowance of Claim 1 on appeal on
29 the record before us would preclude those skilled in the art from practicing an

1 obvious modification of Chen's invention. As *KSR* notes, § 103 is designed to
2 prevent that from happening.

3 When a *Wood* analogous art analysis is made from the point of view of
4 combining the Chen patent and the Wakabayashi publications, it then becomes
5 manifest that the Wakabayashi publications are related to Chen's field of endeavor.
6 On that basis, the patent and publications can be combined to determine whether
7 Claim 1 on appeal is unpatentable under § 103. We agree with the Examiner's
8 observation (Answer, page 21):

9 the fact that Wakabayashi [1] is not concerned with . . .
10 [applicant's] field of endeavor (ostensibly the
11 manufacture of shaped articles from PTT compositions)
12 and solves a problem other than that identified by . . .
13 [applicant] does not preclude the use of . . .
14 [Wakabayashi 1] in a proper rejection under 35 USC [§]
15 103(a).

16 For the reasons given, we reject applicant's argument that Chen and the
17 Wakabayashi publications are non-analogous art which cannot be used to support a
18 § 103 rejection.

19 Magnesium neutralized ionomer

20 Applicant maintains that Chen does not describe the use of magnesium
21 neutralized ionomers. Brief, page 10. In initially describing its second polymeric
22 ionomer component, Chen explicitly describes neutralization with sodium,
23 potassium, zinc, lithium calcium and ammonium ions. Col. 3:56-57. However, in
24 subsequent discussion Chen includes magnesium ions. Col. 6:43. Wakabayashi 2
25 sets out the reasons for neutralizing both the acid and ionomer with magnesium. A
26 mixture of an acid neutralized with magnesium ions and an ionomer neutralized
27 with sodium ions separates. Page 2882, col. 2. Separation is not a desirable

1 property. One skilled in the art would have recognized the benefit of using a blend
2 of magnesium neutralized materials.

3 Detrimental effect of use of acids neutralized with sodium

4 Applicant maintains that the use of sodium neutralized carboxylic acid failed
5 to reduce viscosity. Brief, page 8. Wakabayashi 2 reveals why. One skilled in the
6 art would have used magnesium neutralized vis-à-vis sodium neutralized acid salts
7 in a Chen composition. Sodium neutralized acids tend to phase separate when
8 blended with the ionomer. Wakabayashi, page 2882, col. 2.

9 Unexpected results

10 We, like the Examiner, believe that applicant maintains that it has
11 discovered a new and unexpected result, *viz.*, an ability to reduce PTT (3GP)
12 viscosity while maintaining PTT molecular weight. Brief, page 6; Answer,
13 page 18 (“[a]though not expressly stated, it is believed that . . . [applicant] wishes
14 to establish evidence for unexpected results based on . . . data [in Tables A and B
15 (Brief, pages 7 and 10)] and . . . subsequent discussion of [those] results.”).

16 Relying on experimental data from the Specification, applicant says that its
17 unexpected result is achieved when magnesium acid salts, and not sodium acid
18 salts, are blended with the ionomer. Brief, page 6.

19 A showing of unexpected results generally must be commensurate in scope
20 with a claimed range. *In re Harris*, 409 F.3d 1339, 1344 (Fed. Cir. 2005) (“[T]he
21 record does not show that the improved performance would result if the weight-
22 percentages were varied within the claimed ranges. Even assuming that the results
23 were unexpected, Harris needed to show results covering the scope of the claimed
24 range.”).

1 Based on data set out in Tables A and B⁸ (Brief, page 7), it may be possible
 2 under certain circumstances to achieve applicant's viscosity/molecular weight
 3 desired result.

4 For a variety of reasons, the Examiner declined to give controlling weight to,
 5 i.e., declined to credit, applicant's proffered evidence of unexpected results.

6 The Examiner found that the experimental data is not commensurate in
 7 scope with the breadth of the claims. The Examiner's findings are made apparent
 8 from a "table" on page 19 of the Answer as follows.

Component	Claim 1		Experimental Results	
Polyester composition	poly(trimethylene terephthalate) OR poly(tetramethylene terephthalate)	70-99.6%	Only poly(trimethylene terephthalate)	80-99%
Aliphatic, monofunctional organic acid	organic acid with 4-36 carbon atoms, optionally substituted with a C1-8 alkyl group	amount not specified	Only magnesium stearate, sodium stearate, or sodium behenate	30% or 40%, based on blend with monomer
Monomer derived from an ethylene acid copolymer	copolymerized comonomers of ethylene, at least one C3-8 unsaturated carboxylic acid, and optionally a C3-8 unsaturated carboxylic acid ester, 75-100% neutralized	amount not specified	Only copolymers of ethylene, acrylic or methacrylic acid, and n-butyl acrylate (a C4 unsaturated carboxylic acid ester), 100% neutralized	60% or 70%, based on blend with acid
Ethylene ester copolymer	20-95% ethylene, 0-25% glycidyl acrylate or methacrylate, 0-80% C1-C8 unsaturated carboxylic acid ester	amount not specified	Only EMA-1, comprising 70% ethylene/30% methyl acrylate, or EBACMA-1, containing 70% ethylene/25% n-butyl acrylate/5% glycidyl methacrylate	5% or 10%, based on total blend amount

9 The Examiner found that applicant tested PTT as a polyester composition.
 10 Claim 1 covers the use of both PTT and PTB. Answer, page 19. No PTB testing is
 11 reported. The Examiner also found that applicant's testing related "only [to] a very
 12 narrow range of compounds falling within the . . . [Claim 1] genus for the
 13 remaining components." *Id.* Applicant did not file a Reply Brief responsive to the
 14 Examiner's findings as set out in the Answer.

⁸ The data in Tables A and B are said to be based on experimental work reported in the Specification. We assume that the data are based on actual experimentation and that the Specification's examples are not prophetic.

1 The Examiner’s analysis is consistent with observations made in
2 Wakabayashi 2. Discussing blends with different carboxylic acid salts (MgSt—
3 magnesium stearate), (MgOl—magnesium oleate and MgEt—magnesium erucate),
4 and results set out in Fig. 11, Wakabayashi 2 found that only magnesium stearate
5 crystallizes to reinforce compositions. Page 2862, col. 1. The metal cation used
6 has a substantial impact on phase separation. Wakabayashi 3, page 181. Applicant
7 has not established that the result can be achieved with zinc and calcium cations.
8 Blend behavior is also said to be “quite sensitive to the metal soap chosen”. *Id.*
9 There is no objective evidence that “short” chain acid will achieve applicant’s
10 results. *See n.5, supra.*

11 The Examiner also observed, correctly, that reduced viscosity while
12 maintaining molecular weight is not recited in the claims. Answer, page 20. The
13 Examiner declined, again correctly, to read a viscosity or molecular weight
14 limitation into Claim 1. Accordingly, it is apparent that Claim 1 is not explicitly
15 limited to compositions having the alleged unexpected result. When an applicant
16 alleges an *unclaimed* unexpected result, the burden of establishing results
17 commensurate in scope with a claim may be difficult. On the other hand, when the
18 unexpected result (*e.g.*, a particular property) is claimed, then applicant’s burden is
19 simplified because the applicant can then focus on establishing that the prior art
20 relied upon by an examiner does not achieve the result, or to use the words of
21 *McClain*, the new function. Applicant in this case elected not to claim the result
22 and therefore labored under a burden to establish unexpected results commensurate
23 in scope with the breadth of Claim 1.

24 On the record before us, we have no basis for disagreeing with weight the
25 Examiner assigned to applicant’s unexpected result evidence. *In re Am. Acad of*
26 *Sci. Tech Ctr.*, 367 F.3d 1359, 1368 (Fed. Cir. 2004) (Board has broad discretion as

1 to the weight given to five declarations offered in the course of prosecution); *In re*
2 *NTP, Inc.*, 654 F.3d 1268, 1275 (Fed. Cir. 2011) (Board has discretion as to the
3 weight to give declarations).

4 For the reasons given, we find that applicant has not established that the
5 subject matter of Claim 1 possesses unexpected properties commensurate in scope
6 with the breadth of the claim.

7 **Other arguments**

8 We have considered applicant's remaining arguments and find none that
9 warrant reversal of the Examiner's rejections. *Cf. In re Antor Media Corp.*,
10 689 F.3d 1282, 1294 (Fed. Cir. 2012).

11 **Decision**

12 Upon consideration of the appeal, and for the reasons given herein, it is

13 **ORDERED** that the decision of the Examiner rejecting the claims on
14 appeal under § 103 over the prior art is *affirmed*.

15 **FURTHER ORDERED** that since we have relied on *Wakabayashi 2*
16 and *Wakabayashi 3*, and perhaps have advanced new rationale in support of
17 obviousness, our affirmance is designated as a new rejection. 37 C.F.R.
18 § 41.50(b).

19 **FURTHER ORDERED** that our decision is not a final agency
20 action.

21 **FURTHER ORDERED** that within **two (2) months** from the date of
22 our decision, appellant may further prosecute the application on appeal by
23 exercising one of the two following options:

24 Option 1: Request that prosecution be reopened by submitting
25 an amendment or evidence or both. 37 C.F.R. § 41.50(b)(1).

